Literature DB >> 11286428

Hepatitis C in methadone maintenance patients: prevalence and public policy implications.

J J McCarthy1, N Flynn.   

Abstract

OBJECTIVE: This study measured the extent and examined implications of hepatitis C (HCV) infection in a methadone maintenance treatment (MMT) population.
METHOD: Four hundred and sixty patients were tested for HCV-Ab, hepatic enzymes and bilirubin, HCV-RNA, and hepatitis B antibody.
RESULTS: Overall, 87% of this population had evidence of HCV-Ab. Among drug injectors (IDU), 96% were HCV-Ab positive. Among a subset of Laotian opium-smoking patients prevalence was only 11%. Sixty-two percent of patients with HCV-Ab had detectable HCV-RNA. Only 41% had elevated hepatic enzymes, and 5% had elevated bilirubin levels. All age groups were equally infected. Systemic problems in screening and treating HCV in drug users were identified.
CONCLUSION: HCV infection poses significant long-term health risks for this population. Harm reduction interventions aimed at reducing transmission of HCV and other needle-related infectious disease deserves more consideration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286428     DOI: 10.1300/J069v20n01_03

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  23 in total

1.  Developing a modified directly observed therapy intervention for hepatitis C treatment in a methadone maintenance program: implications for program replication.

Authors:  R Douglas Bruce; Julie Eiserman; Angela Acosta; Ceilia Gote; Joseph K Lim; Frederick L Altice
Journal:  Am J Drug Alcohol Abuse       Date:  2012-01-13       Impact factor: 3.829

Review 2.  Opioids and HIV/HCV infection.

Authors:  Xu Wang; Ting Zhang; Wen-Zhe Ho
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-14       Impact factor: 4.147

Review 3.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

4.  Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: effects on eligibility for hepatitis C treatment.

Authors:  Steven L Batki; Kelly M Canfield; Robert Ploutz-Snyder
Journal:  Am J Addict       Date:  2011-05-31

5.  A pilot training program for a motivational enhancement approach to hepatitis C virus treatment among individuals in Israeli methadone treatment centers.

Authors:  Diane S Morse; Miriam Schiff; Shabtay Levit; Rinat Cohen-Moreno; Geoffrey C Williams; Yehuda Neumark
Journal:  Subst Use Misuse       Date:  2012-01       Impact factor: 2.164

6.  Injection drug users and the provision of hepatitis C-related services in a nationwide sample of drug treatment programs.

Authors:  Zdravko P Vassilev; Shiela M Strauss; Janetta Astone; Don C Des Jarlais
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

7.  Morphine enhances hepatitis C virus (HCV) replicon expression.

Authors:  Yuan Li; Ting Zhang; Steven D Douglas; Jian-Ping Lai; Wei-Dong Xiao; David E Pleasure; Wen-Zhe Ho
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

8.  Upregulation of SOCS-3 and PIAS-3 impairs IL-12-mediated interferon-gamma response in CD56 T cells in HCV-infected heroin users.

Authors:  Li Ye; Xu Wang; David S Metzger; Eric Riedel; Luis J Montaner; Wenzhe Ho
Journal:  PLoS One       Date:  2010-03-09       Impact factor: 3.240

9.  Seroprevalence of HIV, hepatitis b, and hepatitis c among opioid drug users on methadone treatment in the netherlands.

Authors:  Imke Schreuder; Marianne Ab van der Sande; Matty de Wit; Monique Bongaerts; Charles Ab Boucher; Esther A Croes; Maaike G van Veen
Journal:  Harm Reduct J       Date:  2010-10-26

10.  Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran.

Authors:  Parastoo Kheirandish; SeyedAhmad SeyedAlinaghi; MohammadReza Jahani; Hadi Shirzad; MohammadReza Seyed Ahmadian; Ali Majidi; Amirhoushang Sharifi; Mostafa Hosseini; Minoo Mohraz; Willi McFarland
Journal:  J Urban Health       Date:  2009-11       Impact factor: 3.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.